Concorde Asset Management’s Royalty Pharma RPRX Stock Holding History

Concorde Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,168	Closed	-$206K	–	191
2021 Q4	$206K	Sell	5,168 -5,442	-51%	-$211K	0.12%	159
2021 Q3	$383K	Buy	10,610 +22	+0.2%	+$855	0.22%	134
2021 Q2	$434K	Sell	10,588 -582	-5%	-$24.8K	0.24%	108
2021 Q1	$487K	Buy	+11,170	New	+$530K	0.28%	91

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concorde Asset Management's RPRX Position: Q1 2022 in Review

Concorde Asset Management sold out of Royalty Pharma (RPRX) in Q1 2022, closing a stake of 5,168 shares — an estimated $206K sold.

Concorde Asset Management first reported a position in RPRX in Q1 2021 and held it in 4 quarters. The position peaked at $487K in Q1 2021. 279 funds tracked by Wall St. Rank hold RPRX as of Q1 2022.

Concorde Asset Management reported no remaining Royalty Pharma position as of Q1 2022 after selling out during the quarter.
Concorde Asset Management sold 5,168 Royalty Pharma shares in Q1 2022, an estimated $206K.
Concorde Asset Management first reported a position in Royalty Pharma in Q1 2021 and held it in 4 quarters.
Concorde Asset Management's Royalty Pharma position peaked at $487K in Q1 2021.
279 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2022.

Based on Concorde Asset Management's 13F filing for Q1 2022, filed 22 Apr 2022.